Michael Auerbach returns to discuss Subversive's recent deal with leading Israel cannabis company, InterCure and gives an update on The Parent Company. Why Subversive pivoted from a REIT to a SPAC, Canndoc's compelling financials, brands and trading on Nasdaq. Opportunity in GRAMF and other US players still trading at a discount.
Learn more about your ad choices. Visit megaphone.fm/adchoices
